Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC

• Status: Unknown status
• Trial end date: 2019-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The new version of CEUS LI-RADS published at 2018(version 2017). In this study, the investigators aim to investigate the diagnosing performance of CEUS LI-RADS by administrating different contrast agents (SonoVue/ Sonazoid).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Criteria

Inclusion Criteria:

• Patients at risk for HCC with focal liver lesion on conventional ultrasound.

• history of cirrhosis.

• historty of HBV infection.

Exclusion Criteria:

• systemic therapy with sorafenib

• pretreat lesion

• patients don't sign the informed consent.